What is Zilbrysq made of?
Zilbrysq is a medication whose active ingredient is zavegepant [1]. It is formulated as a nasal spray [1].
How does zavegepant work for migraines?
Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. CGRP is a molecule that plays a role in migraine pain. By blocking the CGRP receptor, zavegepant can help reduce migraine symptoms [1].
When is Zilbrysq expected to become available?
Zilbrysq was approved by the U.S. Food and Drug Administration (FDA) in April 2023 for the acute treatment of migraines with or without aura in adults [1].
What other CGRP-targeting migraine treatments are there?
The CGRP pathway is targeted by several other medications, including both small molecule oral antagonists and monoclonal antibody CGRP inhibitors [2]. Examples of oral CGRP antagonists include ubrogepant and rimegepant [2]. Monoclonal antibodies administered by injection include erenumab, fremanezumab, and galcanezumab [2].
What are the potential side effects of Zilbrysq?
Common side effects associated with Zilbrysq include changes in taste, nausea, and nasal discomfort [1].
What is the patent status for Zilbrysq?
Information regarding specific patents and their expiration dates for Zilbrysq can be found on DrugPatentWatch.com [3]. This resource tracks patent exclusivity for many pharmaceutical products.
Who manufactures Zilbrysq?
Zilbrysq is manufactured by Biohaven Pharmaceuticals, which is a subsidiary of Pfizer [1].
How is Zilbrysq administered?
Zilbrysq is administered as a nasal spray, with one spray administered into one nostril [1].
What is the difference between Zilbrysq and other migraine medications?
Zilbrysq is a CGRP receptor antagonist delivered via nasal spray for acute migraine treatment. This differs from triptans, which also target serotonin receptors, and other CGRP-targeting medications that may be oral or injectable and used for acute or preventive treatment [1][2].
---
Sources
1. Biohaven Pharmaceuticals. (2023, April 27). FDA Approves NURTEC® ODT (rimegepant) 75 mg Tablets and ZAVZPRET™ (zavegepant) 10 mg Nasal Spray for the Acute Treatment of Migraine in Adults [Press Release].
2. Edvinsson, L. (2021). CGRP receptor antagonists in migraine treatment. Reviews in the Neurosciences, 32(6), 671-678.
3. DrugPatentWatch.com